PD-1 and PD-L1 Antibodies in Lung Cancer
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.
Read about predictive biomarkers ofPD-1 pathway blockade
Articles in this issue
A Novel Immunotherapy Demonstrates Durable Responses in Metastatic Melanoma
MPDL3280A Induces Durable Responses in NSCLC, Other Cancers
Immunotherapy—An Increasingly Important Role in Oncology
Suzanne Topalian, MD, on PD-1 Targeted Therapy
Understanding Immunotherapy in Cancer: A Q&A with Antoni Ribas, MD, PhD
PD-1 and PD-L1 Antibodies in Lung Cancer
Checkpoint Inhibitors in Cancer Care
Search for Predictive Biomarkers of PD-1 Pathway Blockade
Nivolumab Plus Ipilimumab in Advanced Melanoma
The Outlook for Immunotherapies
Recent Videos
Related Content
Key Trials From ASH 2024 Impact Treatment for Plasma Cell Disorders Going Forward
February 20th 2025Article
Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 ASH Annual Meeting and Exposition.
Read More
